Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Smoking 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma, Mantle-Cell 1Genetic Diseases, Inborn 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Practice Guidelines as Topic 3Standard of Care 2Interviews as Topic 2pembrolizumab 1Watchful Waiting 1Tamoxifen 1Tablets 1Surveys and Questionnaires 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Protons 1Proton Therapy 1Observation 1Methods 1Metformin 1Mastectomy, Segmental 1Hypnosis, Anesthetic 1Exercise 1Educational Status 1Early Intervention, Educational 1Decision Support Techniques 1Counseling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Breast Carcinoma In Situ × Tablets × Clear all
NCT06033092 2025-08-28

TOLERANT

European Institute of Oncology

Phase 2 Active not recruiting
200 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡